Contraceptive drugs and devices Market size was valued at USD 27.94 Billion in 2023

The contraceptive drugs and devices market size was valued at $27.94 billion in 2023, and is estimated to reach $44.87 billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030. The increasing awareness related to STDs and active government initiatives promoting the use of contraceptives are primarily driving the market growth.

Request Sample Link For More Details: https://www.maximizemarketresearch.com/request-sample/206575/

Factors and Opportunities for Market Growth

The increasing rate of unintended pregnancies has highlighted the demand for solutions. With an estimated 74 million unintended pregnancies worldwide, the World Health Organization has noted the importance of making contraceptive methods more easily accessible. This demand is being further supported internationally by government programmes urging aesthetic cleanliness through educational initiatives and subsidising contraceptive products leading to increased family planning and reproductive health.

In addition to all these things, technology has made long-acting reversible contraceptives (LARCs), including intrauterine devices (IUDs) and hormonal implants, available. Stretching the shelf life are liberally marketed innovations that may prevent dirt and stains, and will appeal to a wider audience with features of convenience. In addition, the growing acceptance of male contraceptive is another growing opportunity. Male birth control -- but not birth control -- has never been a reality until recently, and offering a more long-term yet reversible option like a male contraceptive injection "Plan A" has been launched by NEXT Life Sciences recently, showing a potential change in contraception that could split responsibility.

Segmentation Analysis

The contraceptive market can be segmented as drugs and devices, as per different end-user preferences and requirements.

Examples of contraception drugs: oral contraception pills, contraceptive injectables, and topical contraceptives. Oral tablets are still prevalent as they are convenient and readily available. Injectables provide sustained protection, usually lasting between one and three months after each dose, desirable for individuals wanting less frequent doses. Gels and patches give alternatives to those who are sensitive to hormonal-containing pills.

Contraceptive Devices : This segment includes male and female contraceptive devices Examples of these are IUDs, subdermal implants and female condoms, both hormonal and non-hormonal methods. The scope of male contraception refers mainly to the use of condoms and research is continuing with innovative alternatives such as male contraceptive injections and gels intending to provide more options for male!

Want to access more insights? The journey starts from requesting Sample https://www.maximizemarketresearch.com/request-sample/206575/ 

Country-Level Analysis

United States: In the U.S. market, growth is driven by awareness and access to contraceptive methods. Over-the-counter sale of oral contraception, like Opill in the United States, had been approved to increase access to contraception by removing the requirement for prescriptions as a means to ease access and convenience for users.

Germany: Germany has a dominant healthcare scheme that provides access to different contraceptive means to most of the people. The market is growing steadily as government programs and insurances provide for traditional as well modern contraceptives affordability and accessibility.

China: The Chinese market is growing, thanks to state-sponsored family planning policies and rising public awareness of reproductive health A market whose future is looking bright for both population control education and cheap contraceptive options has successfully decreased the rate of unintended pregnancies in the population.

For example, in Australia, the government has improved access to contraception by placing some common birth control pills (like Yaz and Yasmin) on the Pharmaceutical Benefits Scheme (PBS). This decision saves about 50,000 women each year money, making birth control more affordable and more widely available.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report :https://www.maximizemarketresearch.com/market-report/contraceptive-drugs-and-devices-market/206575/

Competitor Analysis

The market for birth control drugs and devices is competitive, with many top players attempting to develop new innovations that meet the changing needs of consumers. Notable companies include:

Pfizer Inc. (U.S.): Well-known, globally active pharmaceutical leader with a selection of contraceptive products on the market and a strong R&D pipeline for various new solutions

Related: Merck & Co., Inc. (US): Expand contraceptive access through education and partnerships.

Teva Pharmaceuticals Ltd (Israel): By attracting price-conscious consumers, Veradigm has increased its market presence with novel contraceptive products by Teva.

Agile Therapeutics, Inc. (United States)-a women-focused company that created Twirla, a weekly drug patch providing a new option for those patients who wish to avoid daily pills.

Allergan plc (Ireland): Portfolio of contraceptive products; Innovation to meet unmet needs in contraception and reproductive health

This is a move towards improving access, with the latest information pointing toOpill now being available over-the-counter in the U.S. Agile Therapeutics also reported clinicial updates on Twirla for women who want new ways to achieve hormonal contraception. As for male contraceptives, NEXT Life Sciences raised funds to progress 'Plan A', a reversible male contraceptive injection, which will enter clinical trials in Australia in early 2025.

Conclusion

The global market for contraceptive drugs and devices is undergoing significant expansion owing to increased knowledge of reproductive health, government initiatives and developing technology. With changing norms and the need for little distinctions in preventative contraception believe that face always in demand, the market is also saturated potentially be much more for innovation.

Related Reports :

♦ Orthopedic Implants Market https://www.maximizemarketresearch.com/market-report/global-orthopedic-implants-market/29218/

♦ Intraoral Scanners market https://www.maximizemarketresearch.com/market-report/intraoral-scanners-market/165094/

♦ Angiography Devices Market https://www.maximizemarketresearch.com/market-report/angiography-devices-market/165164/

♦ Telerehabilitation Market https://www.maximizemarketresearch.com/market-report/telerehabilitation-market/167363/

♦ Cough Syrup Market https://www.maximizemarketresearch.com/market-report/cough-syrup-market/221894/

♦ Australia Teleradiology Market https://www.maximizemarketresearch.com/market-report/australia-teleradiology-market/224271/

♦ Mexico Healthcare Insurance Market https://www.maximizemarketresearch.com/market-report/mexico-healthcare-insurance-market/226290/

♦ Australia Healthcare Insurance Market https://www.maximizemarketresearch.com/market-report/australia-healthcare-insurance-market/226451/

♦ Stent Retriever Market https://www.maximizemarketresearch.com/market-report/stent-retriever-market/227384/

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

sales@maximizemarketresearch.com

+91 9607365656

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

This release was published on openPR.